STAGE III COLON CANCER AJCC V8
Clinical trials for STAGE III COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug may shrink HER2+ colorectal tumors before surgery
Disease control Recruiting nowThis study tests a drug called zanidatamab given before surgery for people with HER2-positive colorectal cancer that has not spread widely. The goal is to see if the drug can shrink tumors and improve outcomes. About 38 adults will take part, and the study is currently recruiting…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 17, 2026 09:22 UTC
-
Immunotherapy after surgery may keep High-Risk colon cancer at bay
Disease control Recruiting nowThis study tests whether the immunotherapy drug toripalimab can lower the chance of cancer coming back after surgery in people with a specific type of high-risk colon cancer (mismatch repair deficient). About 40 participants will receive the drug for up to a year. The main goal i…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New app aims to boost healthy habits in cancer survivors and their families
Knowledge-focused Recruiting nowThis study is creating and testing a mobile health app to help colorectal cancer survivors and their family caregivers follow healthy lifestyle recommendations. The goal is to see if the app is easy to use and helpful. About 70 people who have finished treatment for stage I-III c…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:05 UTC